Hospitalization and thrombolysis or dual antiplatelet therapy in hemiplegic migraine patients: a cohort of 21 patients from a tertiary headache center
Palavras-chave:
Hemiplegic migraine, hospitalization, thrombolysis, dual antiplatelet therapy, stroke mimic, resource-limited setting, cost-effective healthcare, clinical assessment, imaging techniques.Resumo
Introduction: Hemiplegic migraine (HM) is a rare form of migraine that closely mimics stroke, often leading to hospitalizations. In resource-limited settings, distinguishing between HM and stroke is crucial to avoid unnecessary and costly treatments such as thrombolysis (TICI) and dual antiplatelet therapy (DAPT) and their risks. Typically, with clinical and laboratory evaluations alongside computed tomography (CT), the incidence of stroke mimic admissions can be reduced to 4-6.5%. This study aimed to evaluate the hospitalization rates and use of TICI and DAPT in HM patients followed up in a tertiary headache service.
Methods: A retrospective cohort study was conducted on 21 patients diagnosed with HM at our Headache Outpatient Clinic in Fortaleza, Brazil. Data collected included demographics, clinical history, hospitalization status, and treatment details. Statistical analyses were performed to identify correlations between hospitalization and stroke treatments.
Results: The study included 21 HM patients (mean age 37.67 years, SD 9.65; 95.2% female). Hospitalization was required for 66.7% (14/21) of the patients due to suspected acute cerebrovascular events. Among hospitalized patients, 9.5% (2/21) received thrombolysis, and 14.3% (3/21) were administered DAPT, exceeding the typical stroke mimic admission rates of 4-6.5% after CT evaluation. The decision for hospitalization was strongly correlated with suspected stroke (r = 0.90) but the option to perform thrombolysis or prescribe DAPT did not correlate with any of the other variables studied.
Conclusions: Hospitalization due to suspected stroke is common among HM patients. The administration of thrombolysis and DAPT, though limited, exceeds typical rates seen in stroke care. This underscores the need for precise diagnostic criteria and cautious use of costly, risky unnecessary treatments to manage HM effectively especially in resource-limited settings.
Downloads
Referências
Aguilar-Shea AL, Membrilla MD, Díaz-de-Terán J. Migraine review for general practice. Aten Primaria. 2021;54(2):102208. Doi: 10.1016/j.aprim.2021.102208.
Bertels Z, Pradhan AA. Emerging treatment targets for migraine and other headaches. Headache. 2019;59(Suppl 2):50-65. Doi: 10.1111/head.13585.
Boer I, Hansen JM, Terwindt G. Hemiplegic migraine. Handb Clin Neurol. 2024;199:353-365. doi: 10.1016/B978-0-12-823357-3.00015-X.
Bonemazzi I, Brunello F, Pin JN, Pecoraro M, Sartori S, Nosadini M, Toldo I. Hemiplegic migraine in children and adolescents. J Clin Med. 2023;12(11):3783. Doi: 10.3390/jcm12113783.
Di Stefano V, Rispoli MG, Pellegrino N, Graziosi A, Rotondo E, Napoli C, Pietrobon D, Brighina F, Parisi P. Diagnostic and therapeutic aspects of hemiplegic migraine. J Neurol Neurosurg Psychiatry. 2020;91(7):764-771. Doi: 10.1136/jnnp-2020-322850.
Evers S, Tassorelli C. Migraine with aura. Handb Clin Neurol. 2023;198:169-186. Doi: 10.1016/B978-0-12-823356-6.00009-3.
Grangeon L, Lange KS, Waliszewska-Prosół M, Onan D, Marschollek K, Wiels W, Mikulenka P, Farham F, Gollion C, Ducros A; European Headache Federation School of Advanced Studies (EHF-SAS). Genetics of migraine: where are we now? J Headache Pain. 2023;24(1):12. Doi: 10.1186/s10194-023-01547-8.
Harder AVE, Terwindt GM, Nyholt DR, van den Maagdenberg AMJM. Migraine genetics: status and road forward. Cephalalgia. 2023;43(2):333-342. Doi: 10.1177/03331024221145962.
Khan J, Asoom LIA, Sunni AA, Rafique N, Latif R, Saif SA, Almandil NB, Almohazey D, AbdulAzeez S, Borgio JF. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021;139:111557. Doi: 10.1016/j.biopha.2021.111557.
Kumar A, et al. Hemiplegic migraine. In: StatPearls Publishing. Treasure Island: StatPearls Publishing; 2024. [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513302/
Lu G, Xiao S, He J, Xie W, Ge W, Meng F, Yang Y, Yu S, Liu R. Prevalence of depression and its correlation with anxiety, headache and sleep disorders among medical staff in the Hainan Province of China. Front Public Health. 2023 Jun 27;11:1122626. Doi: 10.3389/fpubh.2023.1122626.
Lucas C. Migraine with aura. Rev Neurol. 2021;177(7):779-784. Doi: 10.1016/j.neurol.2021.07.010.
Munksgaard SB, Madsen SK, Wienecke T. Treatment of medication overuse headache- a review. Acta Neurol Scand. 2019;139(5):405-414. Doi: 10.1111/ane.13074
Nandyala A, Shah T, Ailani J. Hemiplegic migraine. Curr Neurol Neurosci Rep. 2023;23(7):381-387. doi: 10.1007/s11910-023-01277-z
Pietrobon D. Familial hemiplegic migraine. NeuroTherapeutics. 2007;4(2):274-284. Doi: 10.1007/s11765-006-0023-x
Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386-398. Doi: 10.1038/nrn1102
Sanchez Del Rio M, Cutrer FM. Pathophysiology of migraine aura. Handb Clin Neurol. 2023;198:71-83. Doi: 10.1016/B978-0-12-823356-6.00015-7
Theije-Kors E, Haan J. Hemiplegic and basilar-type migraine: epidemiology, genetics, and mechanisms. Headache Curr. 2006;3(4):73-81. Doi: 10.1111/j.1743-5013.2006.00
Tolner EA, et al. From migraine genes to mechanisms. Pain. 2015;156(Suppl 1):S64-S74. Doi: 10.1097/j.pain.0000000000000202
Yemisci M, Eikermann-Haerter K. Aura and stroke: relationship and what we have learnt from preclinical models. J Headache Pain. 2019;20(1):63. Doi: 10.1186/s10194-019-1016-0
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Alberto Jorge Castelo Branco Roque, João José Freitas de Carvalho, Raimundo Neudson Maia Alcântara, Mário Hermes Rios França, Virna Victória Almeida Sampaio, Matheus Rolim Mendes de Alencar, Hanne Castelo Branco Roque (Author)
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
